Cytokine profile determined by data-mining analysis set into clusters of non-small-cell lung cancer patients according to prognosis.
暂无分享,去创建一个
O. Arrieta | A. Barrera | L. Barrera | J. L. Bañales-Mendez | L. Ramírez-Tirado | E. Montes-Servín | F. Salinas-Parra | M. Sandoval-Rios
[1] A. Mohar,et al. Effects of an oral nutritional supplement containing eicosapentaenoic acid on nutritional and clinical outcomes in patients with advanced non-small cell lung cancer: randomised trial. , 2014, Clinical nutrition.
[2] L. Collette,et al. Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation fo , 2014, European journal of cancer.
[3] X. Paoletti,et al. Dose‐finding design using mixed‐effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trials , 2013, Statistics in medicine.
[4] R. Pfeiffer,et al. Circulating inflammation markers and prospective risk for lung cancer. , 2013, Journal of the National Cancer Institute.
[5] L. McShane,et al. Circulating levels of immune and inflammatory markers and long versus short survival in early-stage lung cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] J. Bower,et al. Inflammation and cancer-related fatigue: Mechanisms, contributing factors, and treatment implications , 2013, Brain, Behavior, and Immunity.
[7] L. Oñate-Ocaña,et al. Health-related quality of life in patients with lung cancer: validation of the Mexican-Spanish version and association with prognosis of the EORTC QLQ-LC13 questionnaire. , 2012, Lung cancer.
[8] L. Oñate-Ocaña,et al. Association of Nutrition Parameters Including Bioelectrical Impedance and Systemic Inflammatory Response With Quality of Life and Prognosis in Patients With Advanced Non-Small-Cell Lung Cancer: A Prospective Study , 2012, Nutrition and cancer.
[9] Takashi Suzuki,et al. Antitumor activity of type III interferon alone or in combination with type I interferon against human non‐small cell lung cancer , 2011, Cancer science.
[10] D. Bandyopadhyay,et al. Proportional odds model for dose‐finding clinical trial designs with ordinal toxicity grading , 2011, Statistics in medicine.
[11] J. Scheller,et al. The pro- and anti-inflammatory properties of the cytokine interleukin-6. , 2011, Biochimica et biophysica acta.
[12] M. Neurath,et al. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. , 2011, Cytokine & growth factor reviews.
[13] R. Sabat,et al. IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties. , 2010, Cytokine & growth factor reviews.
[14] M. Karin,et al. Immunity, Inflammation, and Cancer , 2010, Cell.
[15] S. Costantini,et al. An approach for understanding the inflammation and cancer relationship. , 2009, Immunology letters.
[16] Alberto Mantovani,et al. Cytokines as a key component of cancer-related inflammation. , 2008, Cytokine.
[17] A. Mantovani,et al. Cancer and inflammation: a complex relationship. , 2008, Cancer letters.
[18] C. Dinarello. Historical insights into cytokines , 2007, European journal of immunology.
[19] S. Brand,et al. Novel interferon-λs induce antiproliferative effects in neuroendocrine tumor cells , 2006 .
[20] O. Feron,et al. Innate immunity and angiogenesis. , 2004, Circulation research.
[21] D. Lacombe,et al. Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] N. Songür,et al. Serum Interleukin-6 Levels Correlate with Malnutrition and Survival in Patients with Advanced Non-Small Cell Lung Cancer , 2004, Tumori.
[23] J. Steinke,et al. 2. Cytokines and chemokines. , 2003, The Journal of allergy and clinical immunology.
[24] L. Coussens,et al. Inflammation and cancer , 2002, Nature.
[25] Y K Cheung,et al. Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities , 2000, Biometrics.
[26] G. Trinchieri,et al. Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers , 1991, The Journal of experimental medicine.
[27] T. Kishimoto,et al. The biology of interleukin-6. , 1989, Blood.
[28] A. Jemal,et al. Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.
[29] อนิรุธ สืบสิงห์. Data Mining Practical Machine Learning Tools and Techniques , 2014 .
[30] Kawsar Ahmed,et al. Early detection of lung cancer risk using data mining. , 2013, Asian Pacific journal of cancer prevention : APJCP.
[31] V. Brouste,et al. Pegylated liposomal doxorubicin and cyclophosphamide in early recurrent ovarian carcinoma: phase I dose-finding study , 2013, Cancer Chemotherapy and Pharmacology.
[32] P. Varlet,et al. Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. , 2011, Neuro-oncology.
[33] S. Brand,et al. Novel interferon-lambdas induce antiproliferative effects in neuroendocrine tumor cells. , 2006, Biochemical and biophysical research communications.
[34] J. Pollard. Tumour-educated macrophages promote tumour progression and metastasis , 2004, Nature Reviews Cancer.
[35] Larry Borish,et al. Cytokines and chemokines , 2003 .
[36] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.